Valine

Valine

SCHEMBL6360907

C=CC(=O)O.CC(C)[C@H](N)C(=O)O

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.71
LMNA P02545 1/20 0.48
GABRP O00591 2/20 0.39
GABRD O14764 2/20 0.39
GABRA1 P14867 2/20 0.39
GABRB1 P18505 2/20 0.39
GABRG2 P18507 2/20 0.39
GABRB3 P28472 2/20 0.39
GABRA5 P31644 2/20 0.39
GABRA3 P34903 2/20 0.39
GABRA2 P47869 2/20 0.39
GABRB2 P47870 2/20 0.39
GABRA4 P48169 2/20 0.39
GABRE P78334 2/20 0.39
GABRA6 Q16445 2/20 0.39
GABRG1 Q8N1C3 2/20 0.39
GABRG3 Q99928 2/20 0.39
GABRQ Q9UN88 2/20 0.39
SLC1A3 P43003 2/20 0.38
SLC1A2 P43004 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Valine SCHEMBL22558018 0.98 SLC7A5 (0.68) SLC7A5LMNAGABRPGABRDGABRA1
Valine SCHEMBL30284821 0.88 SLC7A5 (0.68) SLC7A5LMNAGABRPGABRDGABRA1
Valine SCHEMBL9603102 0.88 SLC7A5 (0.68) SLC7A5LMNAGABRPGABRDGABRA1
Valine SCHEMBL4012840 0.88 SLC7A5 (0.68) SLC7A5LMNAGABRPGABRDGABRA1
Valine SCHEMBL547430 0.88 SLC7A5 (0.75) SLC7A5GABRPGABRDGABRA1GABRB1
Valine SCHEMBL9672476 0.88 SLC7A5 (0.75) SLC7A5GABRPGABRDGABRA1GABRB1
Valine SCHEMBL9088823 0.88 SLC7A5 (0.75) SLC7A5GABRPGABRDGABRA1GABRB1
Valine SCHEMBL4498576 0.86 SLC7A5 (0.65) SLC7A5LMNAGABRPGABRDGABRA1
Valine SCHEMBL28747338 0.85 SLC7A5 (0.88) SLC7A5GABRPGABRDGABRA1GABRB1
Valine SCHEMBL20981544 0.85 SLC7A5 (0.88) SLC7A5GABRPGABRDGABRA1GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111004545-A Color paste for color 3D printing UV photocuring material and preparation method and application thereof 北京印刷学院 2020-04-14 CN disclosed
EP-2570410-B1 1-[(4-HYDROXYPRIDIN-4-YL) METHYL]PYRIDINE-2(1H)-ONE DERIVATIVES, PREPARATION METHODS AND USES THEREOF INST PHARMACOLOGY & TOXICOLOGY ACADEMY MILITARY MEDICAL SCIENCES PLA CHINA (CN) 2018-11-21 EP disclosed
CN-107226812-A One class piperidines thiazole oxime ether methoxy base acrylate derivative and its production and use 南开大学 2017-10-03 CN disclosed
CN-106537557-A Adhesion layer composition, method for forming film by nanoimprinting, and methods for manufacturing optical component, circuit board and electronic apparatus 佳能株式会社 2017-03-22 CN disclosed
US-8921563-B2 1-[(4-hydroxypiperidin-4-yl)methyl]pyridin-2(1H)-one derivatives, preparation methods and uses thereof Institue of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A., China (CN) 2014-12-30 US disclosed
CN-102241667-B 1-[(4-hydroxypiperidine-4-yl) methyl] pyridine-2(1H)-one derivatives, preparation method and use thereof INST PHARM & TOXICOLOGY AMMS 2013-10-23 CN disclosed
US-20130231369-A1 1-[(4-hydroxypiperidin-4-yl)methyl]pyridin-2(1H)-one derivatives, preparation methods and uses thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2013-09-05 US disclosed
EP-2570410-A1 1-[(4-HYDROXYPRIDIN-4-YL) METHYL]PYRIDINE-2(1H)-ONE DERIVATIVES, PREPARATION METHODS AND USES THEREOF Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China (CN) 2013-03-20 EP disclosed
CN-102241667-A 1-[(4-hydroxypiperidine-4-yl) methyl] pyridine-2(1H)-one derivatives, preparation method and use thereof INST PHARM & TOXICOLOGY AMMS 2011-11-16 CN disclosed
CN-1886391-A Teramic acid and threonine as beta-secretase inhibitors HOFFMANN LA ROCHE (CH) 2006-12-27 CN disclosed
EP-1385893-A2 RADIATION CURABLE COATING COMPOSITION DSM IP Assets B.V. (NL) 2004-02-04 EP disclosed
EP-1353893-A1 PROCESS FOR THE PREPARATION OF ESTERS OF (METH)ACRYLIC ACID Dsm N.V. (NL) 2003-10-22 EP disclosed
CN-1434020-A Process for preparing acrylic ester (methacrylic) DSM NV (NL) 2003-08-06 CN disclosed
US-20020168164-A1 Radiation curable coating composition DSM IP ASSETS B.V. (NL) 2002-11-14 US disclosed
US-20020156317-A1 Process for the preparation of esters of (meth)acrylic acid DSM IP ASSETS B.V. (NL) 2002-10-24 US disclosed
WO-2002055473-A1 PROCESS FOR THE PREPARATION OF ESTERS OF (METH)ACRYLIC ACID DSM IP ASSETS B.V. (NL) 2002-07-18 WO disclosed
WO-2002055574-A2 RADIATION CURABLE COATING COMPOSITION DSM NV (NL) 2002-07-18 WO disclosed
EP-0409623-A1 Adhesive composition SOMAR CORPORATION (JP) 1991-01-23 EP disclosed
US-4302460-A 4-Quinolinones having antihypertensive activity THE BOOTS COMPANY LIMITED (GB) 1981-11-24 US disclosed
US-4127720-A ANTIALLERGENS BRISTOL-MYERS COMPANY (US) 1978-11-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231369-A1 1-[(4-hydroxypiperidin-4-yl)methyl]pyridin-2(1H)-one derivatives, preparation methods and uses thereof HTR1A, HTR5A, HTR2C SLC7A5 872/4885LMNA 1346/4885GABRP 457/4885
US-20020156317-A1 Process for the preparation of esters of (meth)acrylic acid ADH1A, PAM, OXGR1 SLC7A5 2436/4885LMNA 3979/4885GABRP 1222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.